Novonesis Launches Optiva® Triticum for Pasta Production
COPENHAGEN, Denmark, August 12, 2026 Novonesis announced the launch of Optiva® Triticum, a new biosolution designed to help pasta...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark, August 12, 2026 Novonesis announced the launch of Optiva® Triticum, a new biosolution designed to help pasta...
NEWARK, Del., Feb. 3, 2026 — The global yeast market is entering a decisive new phase as industrial fermentation...
